Antibody Discovery and Development Seminar

The Antibody Discovery and Development Seminar, hosted by Johns Hopkins Technology Ventures and Bluefield Innovations, will review Bluefield Innovation’s Fall 2019 funding cycle, through which investigators can secure multi-million dollar project funding, which to-date have provided JHU faculty with more than $30M in funding commitments so far.

The event on September 24 will consist of an expert-led seminar that explores state-of-the-art antibody therapeutic discovery. There will be presentations by John Toscano, vice dean of natural sciences in the Department of Chemistry; Joe Pearlberg, vice president of scientific affairs for Deerfield; and Larry Green, founder and CEO of Ablexis and CEO, AlivaMab Discovery Service.

Ablexis created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery and antibody drug development. From university labs to large biopharma companies, Ablexis and Deerfield Management have created a widely utilized antibody drug discovery platform. Johnson & Johnson is one of the latest companies to use the AlivaMab mouse to find antibody-drug candidates for choice targets.

Click here to RSVP.

For questions, contact Nicole Snell at nicole.snell@jhu.edu.